Imicare (Imiquimod)

Imiquimod binds to Toll‑like receptor 7 on immune cells in the skin, triggering the production of interferon‑alpha and other cytokines. This immune activation enhances the body’s ability to recognize and destroy virus‑infected cells and early cancerous cells at the application site.

The dosage regimen for Imicare is determined by the prescribing clinician based on the specific indication, lesion size, and patient factors. The prescriber will provide detailed instructions on how much cream to apply, the frequency, and the total duration of therapy.

Imiquimod is classified as a pregnancy category C drug, meaning risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as it is unknown whether the drug passes into breast milk.

To place an order, submit an enquiry on the Imicare product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with surgical excision or cryotherapy, Imicare offers a non‑invasive, topical option that can be applied at home. Unlike antiviral agents such as podophyllotoxin for warts, imiquimod stimulates the immune system rather than directly targeting the virus, which may result in longer treatment courses but avoids systemic drug exposure.

Imicare should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keeping the cream in a cool, dry place helps maintain its stability and potency throughout its shelf life.

Imicare is a topical cream applied directly to the affected skin area. The prescriber will advise the amount to use, usually a thin layer, and the frequency (e.g., once daily, several times per week). Hands should be washed before and after application, and the treated area should be covered only if instructed.

Serious risks include severe allergic reactions such as anaphylaxis, extensive ulceration of the treated skin, and systemic flu‑like symptoms (fever, chills, malaise). Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or rapidly worsening skin lesions.

Imicare is contraindicated in individuals with known hypersensitivity to imiquimod or any cream components, those with compromised immune systems, and patients with active skin infections at the intended application site. It should also be avoided on mucous membranes, eyes, or broken skin unless specifically directed by a clinician.